IMF Virtual Regional Community Workshop (RCW) - Midwest
Virtual Multiple Myeloma Community Workshop
A virtual multiple myeloma workshop addressing the needs specific to communities in the Midwest Region of the United States.
The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on clinical trials. A member of the IMF Nurse Leadership Board will talk about managing side effects and symptoms of myeloma and its treatments. After each presentation with the experts, attendees will have ample time to ask questions.
Kelly Cox, Senior Director IMF Regional Community Workshops
Morie Gertz, MD, reviews multiple myeloma basics including what myeloma is, common symptoms and side effects, advances in how myeloma is initially diagnosed, the stages of myeloma treatment, induction therapy, transplant, and more.
Al-Ola Abdallah, MD discusses the types of relapsed disease, what doctors consider when selecting a treatment regimen, relapsed/refractory treatment options, how doctors treat triple and penta-class refractory myeloma, updates on clinical trials, and more.
Teresa Miceli, RN, BSN, OCN (IMF Nurse Leadership Board) discusses how patients can manage myeloma-related symptoms and side effects along with side effects brought on by treatment. She outlines the most common side effects for each myeloma drug category, how to prevent infection, and more.
Download the IMF's Multiple Myeloma Informational Booklets:
*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:
- CANOVA Clinical Trial Fact Sheet
clinicaltrials.gov Identifier: NCT03539744
- Phase II Relapsed or Refractory Venetoclax Trial
clinicaltrials.gov Identifier: NCT02899052
- Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib
clinicaltrials.gov Identifier: NCT03314181
With Support From: Amgen, The Binding Site, Bristol Myers Squibb, GSK, Janssen, Karyopharm, and Takeda Oncology
|Even the Odds|
Closed Captions Available